Souhaitez-vous accéder aux communiqués récents ?

ASTRAZENECA ENTERS LICENSING AGREEMENTS WITH LEO PHARMA IN SKIN DISEASES Agreement for development and commercialisation of tralokinumab for atopic dermatitis supports sharper focus on main therapy...

28 June 2016 AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination...

AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of...

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 13 June 2016, the interest of Pascal Soriot, a person discharging managerial responsibilities, in the...

ASTRAZENECA ENTERS COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETIC MEDICINES PORTFOLIO Agreement expands commercial reach for anaesthetics and supports the Company's sharp focus on innovative...

AstraZeneca today announced that it has completed the...

ASTRAZENECA LICENSES ZURAMPIC TO GRÜNENTHAL GMBH IN EUROPE AND LATIN AMERICA Agreement includes rights to the fixed-dose combination of lesinurad and allopurinol in gout AstraZeneca today...

POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR ADULTS WITH TYPE-2 DIABETES AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of...

AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic...

27 May 2016 AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium...